Santa Cruz de Tenerife, 9 de junio de 2025. Molefy Pharma, a biotech company focused on developing innovative therapies for ALS and other neurodegenerative diseases, successfully presented three scientific papers at the ENCALS 2025 Meeting, held in Turin, Italy, reaffirming its commitment to advancing therapeutic innovation in Amyotrophic Lateral Sclerosis (ALS).
The European Network to Cure ALS (ENCALS) is Europe’s foremost collaborative platform for ALS research, gathering leading ALS centers, clinicians, and scientists to foster data harmonization, translational science, and collaborative clinical development across the continent.
During the meeting, Molefy Pharma shared preclinical results on its lead candidate AP-2, a small molecule designed to address TDP-43 proteinopathy—one of the most critical pathological mechanisms in ALS. The presented research included findings on AP-2’s mechanism of action, pharmacological safety, and therapeutic potential in both cellular and animal models.
Podemos poner una quote de alguien: “Our participation in ENCALS reflects our ongoing commitment to rigorous science and cross-border collaboration, The event provided an excellent platform to share our research and to connect with the broader ALS scientific community.”
Molefy Pharma’s involvement also reinforces its strategic focus on building European partnerships to accelerate the development and future commercialization of innovative ALS therapies.
About Molefy Pharma
Founded in 2024, Molefy Pharma is a biotechnology company focused on the development of transformative treatments for neurodegenerative diseases, with an initial emphasis on ALS. Combining scientific excellence, strategic collaboration, and cutting-edge technologies, it is committed to accelerating the discovery of real solutions for patients who need them most.
About ARQUIMEA
ARQUIMEA is a Spanish technology company operating globally, providing innovative solutions and products in highly demanding sectors such as Aerospace, Defense & Security, Science Industry, and Fintech. With a strong commitment to research and development, ARQUIMEA fosters cutting-edge innovation through strategic collaborations.
Media Contact:
Inés García Lartategui
igarcia@arquimea.com
603557026